| SEGMENT INFORMATION |
NOTE
5 – SEGMENT INFORMATION
The
Company’s Chief Executive Officer (“CEO”), was identified as the chief operating decision maker (“CODM”).
The CODM reviews financial information prepared on a consolidated basis, together with disaggregated information about revenues and contributed
profit for the Company’s two reportable segments, Octomera and Therapies, in order to make decisions about resources to be allocated
to the segments and to assess their performance. The Octomera segment reports the results of Octomera LLC and its subsidiaries, which
specialize in providing processing services within the Orgenesis group and to third party customers. The Therapies segment includes all
other group activities. Segment revenues, expenses and contributed profit exclude intersegment transactions.one
The
CDMO does not make operating and investing decisions based on assets and, accordingly, does not review asset information by segment.
Therefore, a measure of segment assets is not disclosed.
Segment
data for the year ended December 31, 2024 is as follows:
SCHEDULE OF SEGMENT REPORTING
| | |
Octomera | | |
Therapies | | |
Eliminations | | |
Consolidated | |
| | |
(in
thousands) | |
| Revenues | |
$ | 533 | | |
$ | 525 | | |
$ | (23 | ) | |
$ | 1,035 | |
| Cost of revenues* | |
| (1,351 | ) | |
| (633 | ) | |
| 710 | | |
| (1,274 | ) |
| Gross profit (loss) | |
| (818 | ) | |
| (108 | ) | |
| 687 | | |
| (239 | ) |
| Cost of development services and research
and development expenses* | |
| (4,530 | ) | |
| (5,169 | ) | |
| 697 | | |
| (9,002 | ) |
| Operating expenses* | |
| (3,557 | ) | |
| (10,716 | ) | |
| 4,178 | | |
| (10,095 | ) |
| Impairment of investment** | |
| (6,509 | ) | |
| (11,829 | ) | |
| - | | |
| (18,338 | ) |
| Share in net income of associated companies | |
| - | | |
| (8 | ) | |
| - | | |
| (8 | ) |
| Profit from deconsolidation | |
| - | | |
| - | | |
| 4,480 | | |
| 4,480 | |
| Other income, net | |
| 1,022 | | |
| (416 | ) | |
| - | | |
| 606 | |
| Depreciation and amortization | |
| (1,558 | ) | |
| (771 | ) | |
| 243 | | |
| (2,086 | ) |
| Loss from extinguishment in connection with
convertible loan | |
| - | | |
| (5,422 | ) | |
| - | | |
| (5,422 | ) |
| Credit loss on convertible loan receivable | |
| - | | |
| - | | |
| - | | |
| - | |
| Financial Expenses, net | |
| (4,682 | ) | |
| 49 | | |
| 125 | | |
| (4,508 | ) |
| Finance fees related
to convertible loans to equity | |
| - | | |
| (4,304 | ) | |
| - | | |
| (4,304 | ) |
| * | | Excluding Depreciation,
amortization and impairment expenses |
| ** | | Relates to impairment
expenses on certain property, plant and equipment. |
Segment
data for the year ended December 31, 2023 is as follows:
| | |
Octomera | | |
Therapies | | |
Eliminations | | |
Consolidated | |
| | |
(in
thousands) | |
| Revenues | |
$ | 68 | | |
$ | 515 | | |
$ | (53 | ) | |
$ | 530 | |
| Cost of revenues* | |
| (9,505 | ) | |
| (690 | ) | |
| 4,421 | | |
| (5,774 | ) |
| Gross profit (loss) | |
| (9,437 | ) | |
| (175 | ) | |
| 4,368 | | |
| (5,244 | ) |
| Cost of development services and research
and development expenses* | |
| (9,211 | ) | |
| (5,811 | ) | |
| 4,711 | | |
| (10,311 | ) |
| Operating expenses* | |
| (37,878 | ) | |
| (7,102 | ) | |
| 9,892 | | |
| (35,088 | ) |
| Impairment of investment | |
| - | | |
| (699 | ) | |
| - | | |
| (699 | ) |
| Share in net income of associated companies | |
| - | | |
| (74 | ) | |
| (660 | ) | |
| (734 | ) |
| Profit from deconsolidation | |
| - | | |
| - | | |
| (5,343 | ) | |
| (5,343 | ) |
| Other income, net | |
| 1 | | |
| 3 | | |
| - | | |
| 4 | |
| Depreciation and amortization | |
| (1,765 | ) | |
| (782 | ) | |
| 987 | | |
| (1,560 | ) |
| Credit loss on convertible loan receivable | |
| - | | |
| (2,688 | ) | |
| - | | |
| (2,688 | ) |
| Loss from extinguishment in connection with
convertible loan | |
| - | | |
| (283 | ) | |
| - | | |
| (283 | ) |
| Financial Expenses,
net | |
| (573 | ) | |
| (2,004 | ) | |
| 78 | | |
| (2,499 | ) |
| * | | Excluding Depreciation,
amortization and impairment expenses |
|